Cardiovascular Properties of a New Cardiotonic Agent

View Full Paper

Ask AI

Bookmark

Why the study?

Does MDL 17,043 improve cardiac contractile force in dog models?

Population

Anesthetized and conscious dogs, and dog heart-lung preparation

Design

Preclinical

Authors

Discussion

Supports inotropic effects in canine HF models; leaves open translation to human therapy.

Does MDL 17,043 improve cardiac contractile force in dog models?

Population

Anesthetized and conscious dogs, and dog heart-lung preparation

Intervention

MDL 17,043 (intravenous injection 0.1-1 mg/kg, constant intravenous infusion 0.03-0.1 mg/kg/min, or 3-30 mg/kg in conscious dogs)

Outcome

Cardiac contractile forcesurrogate

MDL 17,043 demonstrates significant positive inotropic effects in dog models, suggesting potential as a novel treatment for heart failure.

Dage et al. (1982) studied this question.

View Full Paper

Ask AI

Bookmark